.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
US Army
Accenture
Teva
Merck
Cerilliant
Colorcon
Baxter
Julphar
Boehringer Ingelheim

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,514,953

« Back to Dashboard

Which drugs does patent 6,514,953 protect, and when does it expire?


Patent 6,514,953 protects LEXIVA and is included in one NDA. There has been one Paragraph IV challenge on Lexiva.

Protection for LEXIVA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-four patent family members in forty-six countries.

Summary for Patent: 6,514,953

Title: Calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1 -benzyl-2-(phosphonooxy)propylcarbamate
Abstract:The invention relates to calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1 -benzyl-2-(phosphonooxy)propylcarbamate, to processes for its preparation, and to its use in the treatment of diseases caused by retroviruses. ##STR1##
Inventor(s): Armitage; Ian Gordon (Arlesey, GB), Searle; Andrew David (Stevenage, GB), Singh; Hardev (Dartford, GB)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:09/744,051
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Dosage form; Process; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Viiv HlthcareLEXIVAfosamprenavir calciumTABLET;ORAL021548-001Oct 20, 2003ABRXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,514,953

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9815567Jul 18, 1998
PCT Information
PCT FiledJuly 15, 1999PCT Application Number:PCT/EP99/04991
PCT Publication Date:January 27, 2000PCT Publication Number: WO00/04033

International Patent Family for Patent: 6,514,953

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China1324363► Subscribe
China1188422► Subscribe
Colombia5090836► Subscribe
Czech Republic20010219► Subscribe
Czech Republic300447► Subscribe
Germany69904600► Subscribe
Denmark1098898► Subscribe
Algeria2845► Subscribe
Eurasian Patent Organization200100053► Subscribe
Eurasian Patent Organization003191► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
AstraZeneca
US Army
Boehringer Ingelheim
Moodys
Farmers Insurance
US Department of Justice
UBS
Fuji
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot